Novel translational therapeutic strategy by sequencing primary liver cancer genomes

[...]treatment of unresectable or metastatic PLCs is based on systemic chemotherapy. Future perspective and conclusion The recent success of regorafenib in the RESORCE trial(1), which is expected to lead to FDA approval, guarantees the implementation of new clinical trials studying the agent as firs...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) England), 2017-05, Vol.13 (12), p.1049-1052
Main Authors: Glantzounis, Georgios K, Kyrochristos, Ioannis D, Ziogas, Demosthenes E, Lykoudis, Efstathios G, Roukos, Dimitrios H
Format: Article
Language:English
Subjects:
Bioinformatics
Biomarkers
cancer genome
Cancer therapies
Chemotherapy
Clinical trials
Deoxyribonucleic acid
DNA
Drugs
FDA approval
Gastroenterology
Genetic testing
Genomes
hepatocellular cancer
intrahepatic cholangiocarcinoma
Liver cancer
Medical prognosis
Metastasis
Mortality
Mutation
next-generation sequencing
novel oncotargets
Patients
Precision medicine
Studies
umbrella and basket studies
whole-exome sequencing
whole-genome sequencing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[...]treatment of unresectable or metastatic PLCs is based on systemic chemotherapy. Future perspective and conclusion The recent success of regorafenib in the RESORCE trial(1), which is expected to lead to FDA approval, guarantees the implementation of new clinical trials studying the agent as first-line treatment of advanced HCC, as well as its clinical utility in the adjuvant setting. Successful integration of NGS into appropriately designed clinical trials with PLC patients treated according to current guidelines highlight the beginning of a strategic framework toward two directions; first, application of tNGS into umbrella and basket studies allow for the simultaneous identification of distinct genetic subgroups and targeting of these subsets of patients with targeted drugs, from the FDA approved list - this concept could substantially shorten the time required for potential clinical benefit. [...]valid identification of novel oncotargets by WES/WGS patientcentric trials, optimized to meet Lawrence's criteria for large sample sizes(5), paves the way to the discovery of new effective targeted agents.
ISSN:1479-6694
1744-8301
DOI:10.2217/fon-2017-0087